Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Andrew Stacey, AAPOS 2021: Increased Incidence of Retinoblastoma in Europe

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: May 4th 2021

It was great to speak with Andrew Stacey (University of Washington and Seattle Children’s Hospital, Seattle, WA, USA) about his thoughts on the increased incidence of retinoblastoma in Europe.

Questions

  1. Could you give us a brief overview of retinoblastoma, its prognosis and advances in treatment? (00:20)
  2. What was previously known about the incidence of retinoblastoma in Europe? (02:08)

Speaker Disclosure: Andrew Stacey has no financial or non-financial relationships or activities to declare in relation to this interview.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of AAPOS 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup